General surgery sales, which include ECM and breast biopsy products, decreased $0.2 million. Sales of the ECM products were $1.7 million compared to less than $0.1 million in the prior year. This increase in ECM product sales reflected the market launch of our new products by our strategic partner, Synthes. Breast biopsy products were $0.2 million compared to $2.2 million in the prior fiscal year comparable period due to inventory stocking orders placed in the first half of fiscal 2010. Endovascular sales for the six months ended December 31, 2010 were $0.7 million compared to $1.7 million in the prior fiscal year period.
Royalty income for the six months ended December 31, 2010 was $12.5 million, compared to $12.9 million in the comparable prior fiscal year period. Royalty income in the six months ended December 31, 2010 included $9.5 million in Angio-Seal™ royalties and $2.8 million in royalties from Orthovita, Inc. Angio-Seal™ royalties decreased by approximately 4% or $0.4 million in the six months ended December 31, 2010 over the prior fiscal year comparable period. Royalties from Orthovita decreased by approximately 3% or $0.1 million compared to the prior fiscal year period.
Earnings Per Share. For the six months ended December 31, 2010 earnings per share were $0.79, compared to diluted earnings per share of $0.75 and adjusted diluted earnings per share* (which exclude the charges described above) of $0.86 for the same period of fiscal 2010. Positively affecting the year to date fiscal 2011 diluted earnings per share when compared to the prior year was a significantly lower number of weighted average common shares outstanding due to the Company's stock repurchase programs.
During the six months ended December 31, 2010, the Company's total tax-effected equity compensation expense was $1.5
|SOURCE Kensey Nash Corporation|
Copyright©2010 PR Newswire.
All rights reserved